EValuating trEatment RESponses of dupilumab versus omalizumab in Type 2 patients: the EVEREST Trial

Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and asthma are chronic type 2 inflammatory diseases. Dupilumab (DUP), a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4/-13, key and central drivers of type 2 inflammation. Omalizumab (OMZ) is a humanized, monoclonal antibody which blocks the action of IgE. Both DUP and OMZ are approved for the treatment of uncontrolled CRSwNP or nasal polyps and asthma. To contribute to evidence-based decision making for treating respiratory diseases, head-to-head studies are required to investigate the comparative efficacy and safety of these interventions.